LY75/DEC-205 Protein (AA 28-1666) (His tag)
-
- Target See all LY75/DEC-205 (LY75) Proteins
- LY75/DEC-205 (LY75) (Lymphocyte Antigen 75 (LY75))
- Protein Type
- Recombinant
- Protein Characteristics
- AA 28-1666
-
Origin
- Human
-
Source
- HEK-293 Cells
- Purification tag / Conjugate
- This LY75/DEC-205 protein is labelled with His tag.
- Purpose
- Human LY75 / CD205 Protein, His Tag
- Purity
- >90 % as determined by SDS-PAGE.
- Endotoxin Level
- Less than 1.0 EU per μg by the LAL method.
- Top Product
- Discover our top product LY75 Protein
-
-
- Restrictions
- For Research Use only
-
- Format
- Lyophilized
- Buffer
- PBS, pH 7.4
- Storage
- -20 °C
-
- Target
- LY75/DEC-205 (LY75) (Lymphocyte Antigen 75 (LY75))
- Alternative Name
- LY75 (LY75 Products)
- Synonyms
- LY75 Protein, MGC140308 Protein, DEC205 Protein, im:7150926 Protein, si:dkey-78p20.2 Protein, LYT75 Protein, CD205 Protein, DEC-205 Protein, CLEC13B Protein, GP200-MR6 Protein, LY-75 Protein, RGD1565962 Protein, Ly-75 Protein, lymphocyte antigen 75 Protein, CD205 protein Protein, CD302 antigen Protein, LY75 Protein, Cyan7822_2917 Protein, LY5 Protein, ly75 Protein, cd205 Protein, LOC100380704 Protein, LOC100433861 Protein, LOC100483541 Protein, Ly75 Protein
- Background
- Lymphocyte antigen 75 (Ly 75, also known as CD205, CLEC13B, GP200-MR6 and DEC-205, is a type I transmembrane protein that is primarily expressed on dendritic cells and thymic epithelial cells. LY75 functions as an endocytic receptor for antigens. MEN1309/OBT076, the first antibody drug targeting CD205, has shown strong preclinical anti-tumor activity in lymphoma. After being verified as a single drug in vivo, the antibody-drug conjugate has a synergistic effect with the BCL2 inhibitor Venetoclax and the anti-cd20 monoclonal antibody rituximab.
- Molecular Weight
- 190.7 kDa
- NCBI Accession
- NP_002340
-